Viatris (XSWX:VTRS) LT-Debt-to-Total-Asset: 0.34 (As of Mar. 2026)

Viatris XSWX:VTRS +0.62% 60 LT-Debt-to-Total-Asset is 0.34 as of Mar. 2026. GuruFocus rates XSWX:VTRS with a GF Score™ of 60/100 and a GF Value™ of CHF8.89. The stock has 8 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Viatris's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.34.

Viatris's long-term debt to total assets ratio declined from Mar. 2025 (0.37) to Mar. 2026 (0.34). It may suggest that Viatris is progressively becoming less dependent on debt to grow their business.

Viatris (XSWX:VTRS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Viatris LT-Debt-to-Total-Asset Related Terms

Viatris LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Viatris's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris LT-Debt-to-Total-Asset Chart

Viatris Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.36

0.34

Viatris Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.37	0.34	0.33	0.34	0.34

60GF Score

Viatris Inc XSWX:VTRS

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Viatris LT-Debt-to-Total-Asset Calculation

Viatris's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	10087.718	/	29639.181
	=	0.34

Viatris's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	9904.785	/	28999.881
	=	0.34

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.34 mean?

Viatris (XSWX:VTRS) has a LT-Debt-to-Total-Asset of 0.34 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Viatris and its competitors.

Is Viatris' LT-Debt-to-Total-Asset too high?

Viatris' current LT-Debt-to-Total-Asset is 0.34. Overall, Viatris has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.

How does Viatris' LT-Debt-to-Total-Asset compare to NBIX and UTHR?

Viatris' LT-Debt-to-Total-Asset of 0.34 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Viatris and its competitors. Viatris's current LT-Debt-to-Total-Asset is 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Viatris stock overvalued right now?

Viatris (XSWX:VTRS) has a current LT-Debt-to-Total-Asset of 0.34. The stock's GF Value™ is CHF8.89, compared to a current price of CHF13.06 — trading 46.9% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.34. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Viatris (XSWX:VTRS), the current LT-Debt-to-Total-Asset is 0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (XSWX:VTRS) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of CHF13.06 is trading 46.9% above its estimated GF Value™ of CHF8.89.

Key valuation signals for XSWX:VTRS:

LT-Debt-to-Total-Asset: 0.34
GF Value™: CHF8.89 vs. price of CHF13.06 (46.9% above fair value)
GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the XSWX:VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies NBIX UTHR ELAN ALKS HIMS LNTH LQDA ZTS AMRX INDV XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ HKSE:03692 NSE:DIVISLAB

Other Exchanges VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany MYL:Austria

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

60GF Score

Get the complete analysis for XSWX:VTRS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF13.06

Price

CHF8.89

GF Value

View XSWX:VTRS Analysis

See LT-Debt-to-Total-Asset data for all stocks →